RxDoctor Payments Data

Lookman Odejobi, MD

Internal Medicine · Neptune, NJNPI 1306888789

Payments from drug & device makers

$2,053in general payments, 2019–2025

Across 161 payments — averaging $12.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$470
  • Lilly USA, LLC$431
  • AstraZeneca$263
  • Boehringer Ingelheim$140
  • Sanofi-aventis U.S. LLC$94
  • Exact Sciences$90
  • plus $564 from 15 others

What the payments were for

  • Food & beverage$2,044100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,053 in reported general payments places this provider in the 75th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$66,070
Medicare patients
201
Services billed
681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide219$239,601
OzempicSemaglutide150$154,163
EliquisApixaban392$151,526
IngrezzaValbenazine Tosylate19$123,402
JardianceEmpagliflozin119$77,794
JanuviaSitagliptin Phosphate91$70,527
Austedo XrDeutetrabenazine18$49,197
FarxigaDapagliflozin Propanediol108$39,675
TradjentaLinagliptin104$32,086
XareltoRivaroxaban82$30,844
CreonLipase/Protease/Amylase26$29,224
EntrestoSacubitril/Valsartan59$27,157
MounjaroTirzepatide18$27,101
Breo ElliptaFluticasone/Vilanterol49$23,414
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$22,949

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$431$266,702237 claims
Novo NordiskOzempic, Fiasp$470$160,082169 claims
PfizerEliquis$64$151,526392 claims
Boehringer IngelheimJardiance, Tradjenta$140$109,880223 claims
MerckJanuvia$62$70,52791 claims
GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta, Anoro Ellipta$61$62,073121 claims
AstraZenecaFarxiga$263$39,675108 claims
AbbVieCreon, Restasis$13$36,03737 claims
Johnson & JohnsonXarelto$54$30,84482 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Neptune

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →